Ionis completes enrollment in Angelman syndrome drug trial
Ionis Pharmaceuticals Inc. announced the completion of enrollment in the pivotal cohort of its Phase 3 REVEAL study for obudanersen, a drug targeting Angelman syndrome. The company anticipates topline data in the second half of 2027 and plans to initiate another Phase 3 study (CHAMPION) for different genotypes. This comes as Ionis's stock trades near its 52-week high, and the company recently received FDA approval for Tryngolza for severe hypertriglyceridemia, drawing positive analyst ratings.
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
Ionis Pharmaceuticals has completed enrollment in the pivotal cohort (Cohort 1) of its Phase 3 REVEAL study, evaluating obudanersen for Angelman syndrome. This investigational RNA-targeted medicine aims to treat the serious neurodevelopmental disorder, with topline data expected in the second half of 2027. The study represents a significant step towards a potential disease-modifying treatment for Angelman syndrome, a condition with no currently approved therapies.
TimesSquare Mid Cap Growth Strategy Picks Ionis Pharmaceuticals Inc. (IONS) on Clinical Momentum
TimesSquare Capital Management's U.S. Mid Cap Growth Strategy has selected Ionis Pharmaceuticals Inc. (NASDAQ:IONS) for its portfolio, citing the company's novel therapies for unmet needs and robust clinical pipeline. Despite a quarterly portfolio decline, Ionis Pharmaceuticals exhibited strong one-month and 52-week returns, with significant year-over-year revenue growth in Q1 2026. The firm emphasizes its focus on disciplined management teams and companies with durable competitive advantages.
TimesSquare Mid Cap Growth Strategy Picks Ionis Pharmaceuticals (IONS) on Clinical Momentum
TimesSquare Capital Management's U.S. Mid Cap Growth Strategy highlighted Ionis Pharmaceuticals (NASDAQ:IONS) in its Q1 2026 investor letter, noting its novel therapies for unmet needs in neurology and cardiovascular indications. The strategy emphasizes companies with strong competitive advantages and a disciplined management team. While acknowledging Ionis's potential and its 87% year-over-year revenue increase in Q1 2026, the firm suggests that certain AI stocks may offer greater upside and less risk.
Form 144 IONIS PHARMACEUTICALS INC For: 1 July By Investing.com
This article announces that IONIS PHARMACEUTICALS INC filed a Form 144 for July 1. It is a brief, one-sentence news item published by Investing.com, typical of financial news updates. The article does not provide specific details about the Form 144 filing itself beyond the date and company name.
Ionis Pharmaceuticals EVP Schneider sells $2.1m in stock By Investing.com
Ionis Pharmaceuticals' EVP and Chief Clinical Development Officer, Eugene Schneider, sold 26,000 shares of company stock for approximately $2.1 million via a Rule 10b5-1 trading plan, while also acquiring 26,000 shares through stock options. The company's stock has seen a 101% return over the past year but is considered overvalued according to InvestingPro analysis, despite a recent FDA approval for its drug Tryngolza and positive analyst ratings.
Ionis Pharmaceuticals EVP Joseph Baroldi’s spouse sells $451,698 stock
The spouse of Ionis Pharmaceuticals EVP Joseph Baroldi sold 5,635 shares of common stock for $451,698 on June 26, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high, although InvestingPro analysis suggests it may be overvalued. Concurrently, Mr. Baroldi’s spouse also acquired 5,635 shares through option exercises, and the company recently received FDA approval for its drug Tryngolza, leading to positive analyst ratings.
Ionis Pharmaceuticals EVP Schneider sells $2.1m in stock
Eugene Schneider, EVP and Chief Clinical Development Officer at Ionis Pharmaceuticals, sold 26,000 shares of company stock for over $2.1 million, following the exercise of stock options. This transaction occurred amidst a 101% stock return over the past year, though InvestingPro analysis indicates the stock may be overvalued. The sale happened shortly after the company received FDA approval for its drug Tryngolza and appointed a new director.
Form 4 Ionis Pharmaceuticals Inc For: 30 June By Investing.com
This article reports on the filing of Form 4 by Ionis Pharmaceuticals Inc. for the period ending June 30. It provides a brief financial update on the company's stock performance. The article is very concise, primarily serving as an announcement of the filing.
IONS - Ionis Pharmaceuticals Inc Latest SEC Filings
This article provides the latest SEC filing information for Ionis Pharmaceuticals Inc (IONS), including its last closing price, financial overview, key statistics, and performance metrics. It details the company's market capitalization, income, sales, insider and institutional ownership, and various profitability ratios. The report also includes stock performance over different periods and analyst recommendations.
Ionis Pharmaceuticals (IONS) Signs Recordati Deal For Zilganersen Outside The U.S.
Ionis Pharmaceuticals (IONS) has finalized a licensing deal with Recordati for zilganersen, an RNA therapy for Alexander disease, granting Recordati commercialization rights outside the U.S. Ionis will retain U.S. rights and global development leadership, receiving upfront and milestone payments plus potential royalties. This partnership allows Ionis to expand its revenue base while aligning with its neurology strategy and managing risk.
Ionis Pharmaceuticals (IONS) Is Up 9.5% After FDA Expands Tryngolza Label For Severe Hypertriglyceridemia
Ionis Pharmaceuticals (IONS) saw its stock rise 9.5% after the FDA approved an expanded label for its drug Tryngolza (olezarsen). The approval allows Tryngolza to be used for reducing triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, moving beyond its previous indication for familial chylomicronemia syndrome. This expansion positions Tryngolza as the first and only therapy in the US specifically addressing both triglyceride reduction and acute pancreatitis risk in this patient population, potentially influencing Ionis's growth trajectory.
Enterprise value to revenue forward of Ionis Pharmaceuticals, Inc. – SWB:ISI
This article provides the enterprise value to revenue forward for Ionis Pharmaceuticals, Inc. (SWB:ISI). It is a financial snapshot accessible through TradingView, indicating no current trades with the market closed. The page is part of a larger financial data and trading platform.
Price to book forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS
This article briefly highlights the "Price to book forward" metric for Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) within the TradingView platform. It appears to be a financial data point rather than a detailed analysis or news story, found under the company's financials section. The content primarily shows navigation details within TradingView.
Enterprise value to revenue forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS
This article provides the enterprise value to revenue forward for Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) as presented on TradingView. It indicates that the market was closed with no trades occurring at the time the data was captured. The content is presented as a financial overview for the company on the TradingView platform.
Ionis Pharmaceuticals EVP research Eric Swayze sells $839k in stock
Eric Swayze, EVP of Research at Ionis Pharmaceuticals, sold 10,602 shares of company stock for approximately $839,491. This transaction was part of a pre-arranged trading plan, and he still holds a significant number of shares. The sale follows a period where the stock surged over 104%, and comes amidst positive news for Ionis, including FDA approval for a new drug and a new board appointment.
Ionis Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:IONS)
This article provides an overview of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) financials, stock performance, and analyst estimates. Key information includes a current stock price of $81.18, a significant 100.99% increase over the last year, and analyst price targets ranging from $75.00 to $130.00. The company's next earnings report is scheduled for August 5, 2026, with recent reports showing better-than-expected earnings and revenue.
Form 4 Ionis Pharmaceuticals Inc For: 26 June By Investing.com
This article announces the filing of Form 4 by Ionis Pharmaceuticals Inc. on June 26. It is a brief, standard notification of an insider transaction, indicating a change in beneficial ownership of the company's securities. The article provides no further details beyond the company, date, and filing type.
Form 144 IONIS PHARMACEUTICALS INC For: 26 June By Investing.com
This article announces that IONIS PHARMACEUTICALS INC filed a Form 144 on June 26th. The information is presented by Investing.com, a financial markets news source. No further details about the filing are provided within the article body.
IONS Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Ionis Pharmaceuticals, Inc. (IONS) stock, based on analyst opinions. It includes current stock performance, historical highs and lows, volatility metrics, market capitalization, and upcoming earnings dates. The consensus analyst rating suggests a "strong buy" for the stock.
Form 144 IONIS PHARMACEUTICALS INC For: 25 June By Investing.com
This article announces that IONIS PHARMACEUTICALS INC filed a Form 144 on June 25th, 2026. The piece is brief, containing only the filing information and basic stock data for IONS, which saw a 3.63% increase.
Ionis Pharmaceuticals, Inc. Actuals & Estimates (LSE:0JDI)
This article provides an overview of Ionis Pharmaceuticals, Inc. (LSE:0JDI) stock performance, analyst estimates, and financial data. It includes details on the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports. The report also highlights analysts' future price predictions, ranging from $75.00 to $130.00.
Ionis grants Recordati rights to zilganersen for Alexander disease
Ionis Pharmaceuticals has granted global pharmaceutical company Recordati exclusive rights to develop and commercialize zilganersen for Alexander disease (AxD) outside the US, receiving a $30 million upfront payment and future milestone payments. Ionis will retain US commercialization rights and global development leadership. Zilganersen, an investigational RNA-targeted medicine, is currently under FDA review with a PDUFA action date of September 22.
Ionis grants Recordati rights to zilganersen for Alexander disease
Ionis Pharmaceuticals has granted global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen for Alexander disease (AxD) outside the US. Ionis will receive a $30 million upfront payment, additional milestone payments, and tiered royalties. The investigational medicine is currently under review by the FDA with a PDUFA action date of September 22.
Ionis: FDA Label Expansion of Tryngolza Expands Commercial Opportunity; Shares Undervalued
Ionis Pharmaceuticals received FDA approval for the label expansion of Tryngolza, now including adults with severe hypertriglyceridemia. This expansion significantly broadens the commercial opportunity for the drug, which was previously approved for the rarer familial chylomicronemia syndrome. Following the announcement, Ionis shares saw a 2% increase in after-hours trading.
Form 144 IONIS PHARMACEUTICALS INC For: 25 June By Investing.com
This article announces the filing of Form 144 for IONIS PHARMACEUTICALS INC on June 25. It appears to be a very brief notification from Investing.com, providing basic information about the filing and including a significant amount of market data and advertisements. The core content is limited to the announcement itself.
Biopharma bites: Ionis' rare disease deal, Vaxart's COVID-19 funding, Alnylam's AI embrace and more from Definium
This article provides a brief overview of recent developments in the biopharma sector, highlighting Ionis' rare disease deal, Vaxart's funding for COVID-19 related work, and Alnylam's integration of AI. It serves as a collection of quick updates from Definium on various biopharmaceutical companies.
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk
Ionis Pharmaceuticals' stock rose after the FDA approved Tryngolza, a new therapy to lower severe hypertriglyceridemia and reduce pancreatitis risk. The company also signed a licensing agreement with Recordati for its investigational Alexander disease therapy, zilganersen, outside the U.S., bolstering Ionis' commercial pipeline. Tryngolza is expected to be available in the U.S. in July, and zilganersen, currently under FDA review, could become the first disease-modifying treatment for Alexander disease.
Recordati secures ex-U.S. rights to Ionis’ Alexander disease therapy
Recordati has acquired exclusive development and marketing rights outside the U.S. for Ionis Pharmaceuticals' zilganersen, an RNA-targeted medicine for Alexander disease (AxD). This deal involves an upfront payment of $30 million to Ionis, with potential for additional milestone payments and tiered royalties. Zilganersen is an investigational therapy that has shown promise in clinical trials by stabilizing gait speed in AxD patients and could become the first disease-modifying treatment for this rare neurological disorder.
Ionis' Tryngolza claims critical label expansion in US
Ionis' drug Tryngolza has received FDA approval for severe hypertriglyceridaemia (sHTG), significantly expanding its target patient population from 3,000 to around 3 million people in the US. This approval is crucial for the drug to meet its blockbuster sales expectations, as it has demonstrated the ability to reduce triglycerides and the risk of acute pancreatitis. To support this broader market, Ionis has substantially lowered the drug's annual list price from $595,000 to $40,000.
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
Ionis Pharmaceuticals has entered into a license agreement with Recordati, granting Recordati exclusive rights to develop and commercialize zilganersen for Alexander disease (AxD) in all countries outside the U.S. Ionis will retain commercial responsibility within the U.S. and continue global development. The agreement involves an upfront payment of $30 million to Ionis, with potential for further milestone payments and royalties.
Ionis hands rare-disease drug zilganersen rights outside the U.S.
Ionis Pharmaceuticals has licensed exclusive rights to develop and commercialize its investigational RNA-targeted medicine, zilganersen, for Alexander disease (AxD) outside the U.S. to Recordati. Ionis retains full commercial responsibility for zilganersen in the U.S., where it is currently under FDA review with a PDUFA action date of September 22. Ionis will receive an upfront payment of $30 million from Recordati, along with additional milestone payments and tiered royalties on net sales.
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
Ionis Pharmaceuticals has entered into a license agreement with Recordati, granting Recordati exclusive rights to develop and commercialize zilganersen for Alexander disease (AxD) in all countries outside the U.S. Ionis will retain commercial responsibility within the U.S. and continue global development, while Recordati will handle regulatory filings and commercialization ex-U.S. The agreement includes an upfront payment of $30 million to Ionis, with potential for additional milestone payments and tiered royalties.
Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Ionis Pharmaceuticals announced that the FDA has approved Tryngolza for the treatment of severe hypertriglyceridemia. This news was reported by Reuters and is less than a minute read. The company's stock symbol is IONS.
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
Ionis Pharmaceuticals, Inc. announced that the FDA has approved TRYNGOLZA® (olezarsen) for severe hypertriglyceridemia (sHTG), making it the first and only treatment indicated to reduce both triglycerides and the risk of acute pancreatitis in affected adults. The approval is based on positive Phase 3 study results showing significant triglyceride reductions and prevention of acute pancreatitis events. TRYNGOLZA will be available in the U.S. in July and is self-administered once monthly.
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
Ionis Pharmaceuticals' drug TRYNGOLZA® (olezarsen) has received FDA approval as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG). The drug, self-administered once monthly, demonstrated significant triglyceride reduction and a decrease in acute pancreatitis events in Phase 3 trials. This approval offers a new treatment paradigm for sHTG patients, who face a high risk of debilitating and life-threatening pancreatitis attacks.
3 US Drug Stocks With Domestic Manufacturing And Trade Risk Exposure
This article identifies three U.S. drug manufacturing stocks—Ionis Pharmaceuticals, Repligen, and Mirum Pharmaceuticals—that are well-positioned amidst rising trade tensions and drug pricing scrutiny, particularly concerning Germany's policies and new U.S. Section 301 investigations. These companies benefit from significant domestic manufacturing operations, potentially shielding them from supply chain disruptions and tariffs. The analysis highlights each company's financial overview, market capitalization, operational specifics, and how their U.S.-centric production offers an advantage in the current global economic climate.
How Olezarsen’s Longer-Term Hepatic Data and High Retention Could Shape Ionis Pharmaceuticals (IONS) Investors
Ionis Pharmaceuticals' olezarsen drug for severe hypertriglyceridemia showed positive longer-term data in a CORE-OLE extension study, including sustained safety, improved liver fat, and high patient retention. This data strengthens the drug's clinical profile, but investors still face uncertainties related to pricing and label decisions, especially with an upcoming FDA PDUFA date of June 30, 2026. While optimistic analysts project significant revenue and earnings, pricing pressures could impact future upside.
Ionis Pharmaceuticals Inc (IONS) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides a financial overview of Ionis Pharmaceuticals Inc (IONS), focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and reports no available data for stock splits. The page displays current stock metrics such as its market capitalization and P/E TTM ratio.
Ionis Pharmaceuticals Inc (IONS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Ionis Pharmaceuticals Inc (IONS) has an earnings forecast score of 8.30, ranking 140th in the Biotechnology & Medical Research industry. Analysts have an average price target of $87.00 for IONS, with a majority recommending a "Buy" trend. The company's expected revenue for the next quarter is $189.69 million, and the EPS is projected at -$1.09.
Ionis Pharmaceuticals Inc (IONS) Valuation: PE, PB & Fair Value Analysis
Ionis Pharmaceuticals Inc (IONS) currently holds a valuation score of 9.16, placing it 56th out of 388 companies in the Biotechnology & Medical Research industry. Its current P/E ratio is -36.80, which is significantly below its recent high and above its recent low. However, relevant data for Price-to-Book (P/B), Price-to-Sales (P/S), and Price-to-Cashflow (P/CF) ratios have not yet been disclosed by the company.
Ionis Pharmaceuticals Inc (IONS) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a detailed risk assessment for Ionis Pharmaceuticals Inc (IONS), highlighting its current risk score of 8.34, ranking it 5th out of 388 in the Biotechnology & Medical Research industry. Key metrics such as beta (0.38), maximum drawdown, volatility, and Sharpe Ratio are presented to illustrate the stock's performance and risk characteristics. The report indicates that IONS tends to underperform in bull markets but offers smaller declines in bear markets.
Ionis Pharmaceuticals Inc (IONS) Financial Health: Profitability & Balance Sheet Analysis
Ionis Pharmaceuticals Inc (IONS) currently holds a financial score of 8.35, placing it 46th in the Biotechnology & Medical Research industry. Despite a classification of weak financial status, the company demonstrates high operating efficiency, reporting a significant year-over-year revenue increase of 86.98% to $246.09M and a net profit increase of 37.03%. The article provides an overview of various financial health dimensions, though stating that detailed relevant data has not yet been disclosed by the company for several categories.
IONS Maintained by Leerink Partners -- Price Target Raised to $1
Leerink Partners has maintained an "Outperform" rating for Ionis Pharmaceuticals (IONS) and raised its price target from $114.00 to $122.00, reflecting confidence in the company's prospects. Despite this positive analyst outlook, Ionis Pharmaceuticals is considered overvalued by 36.5% according to GuruFocus's GF Value™, and has shown significant insider selling activity totaling $32.8 million over the last three months. The company's GF Score™ of 69/100 indicates solid overall performance, but with weaker financial strength and profitability.
Ionis Pharmaceuticals director sells $587,920 in stock
Spencer R. Berthelsen, a director at Ionis Pharmaceuticals Inc. (NASDAQ:IONS), sold 8,000 shares of company stock for $587,920 on June 15, 2026, after exercising options for an equal number of shares. The sale was executed under a Rule 10b5-1 trading plan, and he now directly holds 156,013 shares. This transaction follows recent positive developments for Ionis, including advancements in an Alzheimer's drug, increased revenue guidance, and favorable analyst ratings.
Ionis Pharmaceuticals director sells $587,920 in stock By Investing.com
Ionis Pharmaceuticals director Spencer R. Berthelsen sold 8,000 shares of company stock for $587,920 on June 15, 2026, after exercising non-qualified stock options. This sale was conducted under a Rule 10b5-1 trading plan. Despite the sale, Ionis Pharmaceuticals has seen positive developments, including advancement of an Alzheimer’s drug, increased revenue guidance, and favorable Phase 3 data for a hepatitis B treatment from partners, leading to positive analyst ratings.
Ionis Pharmaceuticals director sells $587,920 in stock By Investing.com
Ionis Pharmaceuticals director Spencer R. Berthelsen sold 8,000 shares of the company's stock for $587,920 after exercising stock options. This transaction was part of a Rule 10b5-1 trading plan. The company has also seen positive developments such as its Alzheimer's drug advancing to registrational development and an increased full-year revenue guidance, leading analysts to raise price targets.
Ionis Pharmaceuticals(IONS.US) Officer Sells US$4.47 Million in Common Stock
An officer at Ionis Pharmaceuticals (IONS.US) recently sold a significant amount of common stock, totaling US$4.47 million. This transaction involved the disposal of 119,742 shares.
Liquidity Mapping Around (IONS) Price Events
This article provides a liquidity mapping analysis for Ionis Pharmaceuticals Inc. (NASDAQ: IONS), highlighting divergent sentiment across all time horizons, suggesting choppy market conditions. It identifies elevated downside risk due to a lack of long-term support signals and presents three AI-generated trading strategies: a Long Entry Zone position trading strategy, a Momentum Breakout strategy, and a Risk Hedging strategy. The analysis also includes multi-timeframe signal analysis indicating neutral near-term, weak mid-term, and strong long-term signals.
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced its participation in several upcoming investor conferences, including the 23rd Annual Needham Virtual Healthcare Conference, the 2024 RBC Capital Markets Global Healthcare Conference, the BofA Securities Health Care Conference 2024, and the 45th Annual Goldman Sachs Global Healthcare Conference. Management will hold fireside chats at these events, with live webcasts and replays available on the company's investor relations website. Ionis, a pioneer in RNA-targeted medicines, will highlight its current five marketed medicines and leading pipeline in neurology and cardiology.
